Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 8/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394060 | 0.87 | NR3C1 (0.53) | NPC1RAB9APGRNR3C1AR | |
| SCHEMBL2395174 | 0.81 | PGR (0.43) | ALDH1A1KDM4EHPGDPGRKMT2A | |
| SCHEMBL2393569 | 0.80 | PGR (0.45) | ALDH1A1LMNAKDM4EHPGDHTT | |
| SCHEMBL2397569 | 0.78 | PGR (0.45) | ALDH1A1HPGDPGRNR3C1PPIA | |
| SCHEMBL2389903 | 0.78 | NR3C1 (0.43) | ALDH1A1LMNAKDM4EHPGDPGR | |
| SCHEMBL2393220 | 0.77 | PGR (0.46) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL2395912 | 0.74 | KDM4E (0.46) | NPC1RAB9AALDH1A1LMNAKDM4E | |
| SCHEMBL2395158 | 0.74 | PGR (0.45) | ALDH1A1KDM4EHPGDPGRKMT2A | |
| SCHEMBL2389906 | 0.71 | PGR (0.44) | PGRNR3C1AR | |
| SCHEMBL2392689 | 0.70 | PGR (0.50) | ALDH1A1KDM4EHPGDPGRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1944290-A1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944290-A1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, NR5A1 | NPC1 2560/4885RAB9A 1172/4885ALDH1A1 3569/4885 |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | NR3C1, NR3C2, NR5A1 | NPC1 186/4885RAB9A 2952/4885ALDH1A1 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.